Explore

Trendline Trendline
Thermo Fisher Scientific Partners with HealthVerity to Enhance Real-World Data in Clinical Research

Thermo Fisher Scientific Partners with HealthVerity to Enhance Real-World Data in Clinical Research

Thermo Fisher Scientific Partners with HealthVerity to Enhance Real-World Data in Clinical Research
Trendline Trendline
FDA Approves Travere's Filspari as First Treatment for Rare Kidney Disease FSGS

FDA Approves Travere's Filspari as First Treatment for Rare Kidney Disease FSGS

FDA Approves Travere's Filspari as First Treatment for Rare Kidney Disease FSGS
Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul
Trendline Trendline
Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial
Trendline Trendline
Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors to Disclose Clinical Trial Results, Addresses Publication Bias

FDA Urges Over 2,200 Sponsors to Disclose Clinical Trial Results, Addresses Publication Bias

The U.S. Food and Drug Administration (FDA) has reminded more than 2,200 medical product companies and researchers to submit clinical trial results to ClinicalTrials.gov. The agency highlights the issue of publication bias, where negative trial results are often not disclosed, leading to a skewed perception of drug efficacy and safety. The FDA's initiative aims to ensure transparency and improve public access to clinical data. The agency has sent messages to companies and researchers to encourage voluntary compliance with reporting requirements, emphasizing the ethical obligation to disclose all trial outcomes.
Trendline Trendline
AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026

AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026

AmacaThera's Non-Opioid Pain Relief Solutions Highlighted at LSX2026
Rapid Read Rapid Read
Scripps Research Develops New Molecules for Autoimmune Disease Treatment

Scripps Research Develops New Molecules for Autoimmune Disease Treatment

Scripps Research scientists have developed a new class of drug compounds called ENDOtollins, which aim to treat autoimmune diseases by reducing harmful inflammation without compromising the body's infection-fighting capabilities. These compounds work by disrupting a specific interaction between two proteins within immune cells, a process described as a 'molecular handshake.' The research, published in Nature Chemical Biology, suggests that these compounds could offer more precise treatment options for conditions like lupus, rheumatoid arthritis, and juvenile arthritis, which affect over 15 million Americans. The study highlights the potential of ENDOtollins to target inflammation pathways specifically, avoiding the broad suppression of the immune system that current treatments often entail.
Rapid Read Rapid Read
Study Reveals Unexpected Detection of Tuberculosis DNA in US-Born Patients

Study Reveals Unexpected Detection of Tuberculosis DNA in US-Born Patients

A recent study has uncovered an unexpectedly high prevalence of Mycobacterium tuberculosis DNA in respiratory samples from predominantly US-born patients hospitalized in Boston. The research, conducted over six years, utilized the 'Totally Optimized PCR (TOP) TB assay,' an ultrasensitive molecular assay, to detect TB-DNA in 12 to 16% of samples. This finding suggests a potential association between M. tuberculosis and various clinical syndromes in patients with a low pre-test probability of TB. The study highlights the need for more sensitive diagnostic tools to identify early stages of TB disease, as current methods may not detect low bacterial loads. The results, while preliminary, indicate a possible new variant of paucibacillary TB disease that remains unrecognized by existing diagnostic technologies.
Trendline Trendline
FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time
Trendline Trendline
Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results

FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results

The U.S. Food and Drug Administration (FDA) has issued reminders to more than 2,200 medical product companies and researchers about their obligation to submit clinical trial results to ClinicalTrials.gov. This action addresses the issue of non-disclosure of trial results, which can lead to publication bias and a skewed perception of drug efficacy and safety. According to the FDA, nearly 30% of studies that should report results have not done so, particularly those involving FDA-regulated products. The agency's reminders aim to encourage voluntary compliance before considering further regulatory actions.